Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

prnasiaJune 07, 2021

Tag: Ascletis , CHB , ASC42

PharmaSources Customer Service